광장공포증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Agoraphobia Treatment Market size is expected to reach USD 2.63 Billion in 2034 from USD 1.95 Billion (2025) growing at a CAGR of 3.37% during 2026-2034.

The global agoraphobia treatment market has gained importance as mental health awareness increases worldwide. Agoraphobia is an anxiety disorder characterized by intense fear of situations where escape may be difficult, often leading individuals to avoid public spaces or crowded environments. Growing recognition of mental health conditions and improved access to psychological care have contributed to the development of treatment services for this disorder.

Several factors are driving growth in the agoraphobia treatment market. Increasing stress levels, lifestyle changes, and rising awareness about mental health have encouraged individuals to seek professional help for anxiety-related disorders. Advances in psychological therapies, including cognitive behavioral therapy, have improved treatment effectiveness and expanded available care options.

Future prospects for the agoraphobia treatment market appear positive as healthcare systems place greater emphasis on mental health support. The growing use of teletherapy and digital mental health platforms may improve accessibility for patients who find it difficult to attend in-person therapy sessions. Continued research and improved mental health services are likely to drive further growth in this market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Treatment

• Selective Serotonin Reuptake Inhibitor
• Norepinephrine Reuptake Inhibitor
• Tricyclic Antidepressant
• Anti-Anxiety Medication
• Others

By Therapy

• Psychotherapy
• Cognitive Behavioral Therapy
• Exposure Therapy
• Others

By End User

• Hospital
• Clinic
• Academic
• Others

COMPANIES PROFILED

• Mylan Pharmaceuticals, Inc, GlaxoSmithKline Plc, Apotex Corp, AstraZeneca, Eli Lilly Co, Pfizer, Inc, Johnson Johnson, Sandoz, Inc, BristolMyers Squibb, Lundbeck AS
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AGORAPHOBIA TREATMENT MARKET: BY DRUG TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Treatment
• 4.2. Selective Serotonin Reuptake Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Norepinephrine Reuptake Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Tricyclic Antidepressant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Anti-Anxiety Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AGORAPHOBIA TREATMENT MARKET: BY THERAPY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy
• 5.2. Psychotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cognitive Behavioral Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Exposure Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AGORAPHOBIA TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AGORAPHOBIA TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Treatment
  • 7.2.2 By Therapy
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Treatment
  • 7.3.2 By Therapy
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Treatment
  • 7.4.2 By Therapy
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Treatment
  • 7.5.2 By Therapy
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Treatment
  • 7.6.2 By Therapy
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL AGORAPHOBIA TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Mylan PharmaceuticalsInc
  • 9.2.2 GlaxoSmithKline Plc
  • 9.2.3 Apotex Corp
  • 9.2.4 AstraZeneca
  • 9.2.5 Eli Lilly & Co
  • 9.2.6 PfizerInc
  • 9.2.7 Johnson & Johnson
  • 9.2.8 SandozInc
  • 9.2.9 Bristol-Myers Squibb
  • 9.2.10 Lundbeck A/S